arrow_rightarrow_righticon_excelicon_pficon_ppticon_wordmagnifier

Thursday 22 September

Please find below the programme schedule for Thursday 22 September 2022.

Thursday 22 Sep

Meet the experts session 1

08:00

M1.1 Diagnostic Rounds Interactive session for diagnosis of emerging and re-emerging fungal infections

Birgit Willinger, Austria and Jurgen Prattes, Germany

08:00

M1.2 Human Pythiosis

Ariya Chindamporn, Thailand and Rongpong Plongla, Thailand

08:00

M1.3 Standardization of diagnostic mycology laboratories

Malcolm Richardson, UK and Amir Seyedmousavi, USA

09:00

Key note (P3): Progress in fungal diagnostics: the pros and cons

Cornelia Lass Flörl, Austria

10:00

Break

Parallel session 4

Parallel session 4 will take place from 10:30 hrs. until 12:00 hrs. and consists of five symposia.

S4.1 Treatment of Rare Mould Infections in 2021: The role of new and old antifungals

Chair: Martin Hoenigl, Austria

10:30

S4.1a Fusariosis: MICs, Mono versus CombinationTherapy and Fosmanogepix

Martin Hoenigl, Austria

10:50

S4.1b Lomentosporiosis: From Voriconazole/Terbinafine combination to Olorofim

Danila Seidel, Gemany

11:10

S4.1c Rasamsonia and Paecilomyces/Purpureocillium: Current state of the art and new treatment options

Rosanne Sprute, Germany

11:30

S4.1d In vitro activity of eight antifungals against 3,343 filamentous pathogenic fungi collected during 18 years at the French National Reference Center for invasive Mycosis and Antifungals

Dea Garcia-Hermoso, France

12:45

Q&A with all speakers

S4.2 Advances in Diagnosis of Invasive fungal infection

Chair: Boualem Sendid, France

10:30

S4.2a Advances in the diagnosis of invasive fungal infection: invasive candidiasis

Boualem Sendid, France

10:50

S4.2b Invasive aspergillosis

Katrien Lagrou, Belgium

11:10

S4.2c Invasive mucormycosis

Hariprasath Prakash, India

11:30

S4.2d Efficacy of LD Bio Aspergillus ICT Lateral flow assay for serodiagnosis of chronic pulmonary aspergillosis

Animesh Ray, India

11:45

Q&A with all speakers

S4.3 Emergent species of the Candida genus

Chair: Neil Gow, UK, Niranjan Nayak, India

10:30

S4.3a Candida tropicalis - molecular mechanism of drug resistance and detection

Anup Ghosh, India

10:50

S4.3b Candida glabrata-host interaction

Bernhard Hube, Germany

11:10

S4.3c Candida glabrata, new tools to study stress, pathogenesis and drug resistance’

Jane Usher, UK

11:30

S4.3d Mechanism of fluconazole resistance in Candida vulturna, a member of the Candida haemulonii complex of multidrug resistant yeasts

Guillermo Garcia Effron, Argentina

11:45

Q&A with all speakers

S4.4 International Histoplasmosis Advocacy group (IHAG)

Chairs: Beatriz Gomez, Colombia, Tom Chiller, USA and Diego Caceres, USA

10:30

S4.4a Global burden of histoplasmosis

Antoine Adenis, France

10:50

S4.4b Progress on iHAG “100 by 25”

Tom Chiller, USA

11:10

S4.4c Histoplasmosis outside the traditional endemic region

Rita Oladele, Nigeria

11:30

S4.4d

TBD

11:45

Q&A with all speakers

S4.5 Mycetoma Clinical Trial on fosravuconazole treatment in eumycetoma– Top Line Results

Chair: Ed Zijlstra, Switzerland

10:30

S4.5a A randomized, double blind phase ii proof-of-concept superiority trial of fosravuconazole 200 mg or 300 mg weekly dose versus itraconazole 400 mg daily, all three arms in combination with surgery, in patients with eumycetoma in Sudan – Top Line Results

Ahmed Hassan Fahal, Sudan

10:50

S4.5b A randomized, double blind phase II proof-of-concept superiority trial of fosravuconazole 200 mg or 300 mg weekly dose versus itraconazole 400 mg daily, all three arms in combination with surgery, in patients with eumycetoma in Sudan – PK results

Borna Nyaoke, Kenya

11:05

S4.5c Using serum beta-glucan measurements and sequencing of the Madurella mycetomatis azole target gene to predict therapeutic outcome during azole treatment in human mycetoma

Wendy van de Sande, Netherlands

11:20

S4.5d Comparing the diagnostic performance of the commonly used eumycetoma diagnostic tests using sequencing of the internally transcribed spacer region as the golden standard

Emmanuel Edwar Siddig, Sudan

11:35

General discussion

12:00

Lunch and Poster session 2

Key note 4 (P4): COVID-19 associated fungal infections

Martin Hoenigl, Austria

Parallel session 5

Parallel session 5 will take place from 15:00 hrs. until 16:30 hrs. and consists of five symposia.

S5.1 Antifungal Resistance

Chairs: Jacques Meis, Netherlands and Danila Seidel, Germany

15:00

S5.1a Candida Tropicalis: Increasing Resistance

Yee-Chun Cheng, Taiwan

15:20

S5.1b Azole-resistance in Aspergillus fumigatus: Clinical implications in haematological patients

Danila Seidel, Germany

S5.1c Resistance in rare fungal infections

Ashutosh Singh, India

16:00

S5.1d Mechanisms of azole antifungal resistance in clinical isolates of Candida tropicalis

Anup Ghosh, India

16:15

Q&A with all speakers

S5.2 The threat of invasive fungal infections: the first WHO list of fungal pathogens of public health importance

Chairs: TBD

15:00

S5.2a Development of WHO priority pathogens list of public health importance

Justin Beardsley, Australia

15:20

S5.2b AMR fungal infections global burden: surveillance challenges, gap & opportunities: WHO GLASS pilot

Daniel Marcano,WHO HQ

15:40

S5.2c WHO first antifungals clinical & preclinical pipeline review

TBD

16:00

S5.2d Current state of research and development of antifungals treatment and diagnostics

Orla Morrissey, Australia

16:15

Q&A with all speakers

S5.3 Cellular pleomorphism and fungal virulence

Chairs: Rupinder Kaur, India and Dee Carter, Australia

15:00

S5.3a Unraveling the genetic determinants of virulence in Cryptococcus

Katrina Jackson, USA

S5.3b Fungal spores: Initiators of colonization and infection

Tim Baltussen, Netherlands

15:40

S5.3c Investigating the link between pleomorphism and virulence in Cryptococcus

Kenya Fernandes, Australia

16:00

S5.3d How mitochondrial complex I proteins in Candida albicans moderate phagocytosis and the production of pro-inflammatory cytokines in murine macrophages and dendritic cells

Xiaodong She, China

16:15

Q&A with all speakers

S5.4 Free oral paper session

Chair: TBD

15:00

S5.4a Cutaneous manifestations of deep fungal infections: a retrospective study from one tertiary hospital

Peiran Chen, China

15:20

S5.4b Genomic variation structure in clinical isolate collections alters benefits of association screening: a study of Cryptococcus neoformans var. grubii in Colombia

Oliver Keatinge Clay, Colombia

15:40

S5.4c Isolation of keratinophilic fungi of the genus Microsporum from the soils of Moscow, Russia

Marina Manoyan, Russia

16:00

S5.4d Agrochemicals potentiate multidrug resistance and alter virulence in Cryptococcus neoformans via hitch-hiking effect of aneuploidy

Liuliu Sun, China

S5.5 Genomic Epidemiology of Fungal Infections

Chairs: Anastasia, Litvintseva, USA and Nancy Chow, USA

15:00

S5.5a Standing Up FungiNet: Genomic epidemiology and surveillance of fungal diseases

Nancy Chow, USA

15:20

S5.5b WGS typing for outbreak investigations

Alexandre Alanio, France

15:40

S5.5c Future of molecular typing in fungi

David Engelthaler, USA

16:00

S5.5d SARS-CoV-2 associated Invasive fungal sinus infections; The Sri Lankan perspective

Liyanage Shamithra

16:15

Q&A with all speakers

16:30

BReak

Parallel session 6

Parallel session 6 will take place from 16:45 hrs. until 18:15 hrs. and consists of five symposia.

S6.1 Antifungal Prophylaxis in Children with Cancer and HSCT

Chair: Andreas Groll, Germany

16:45

S6.1a What do pediatric guidelines recommend?

Adilia Warris, UK

17:05

S6.1b Challenges in antifungal prophylaxis in the real life setting

TBD

17:25

S6.1c Potential utility of extended dosing regimens

Andreas Groll, Germany

17:45

S6.1d First case report of paediatric blood stream infection by Candida magnoliae in a known case of B cell ALL post induction chemotherapy in Central India

Subhasish Bhadra, India

18:00

Q&A with all speakers

S6.2 Resurgence of dermatophytic infections

Chairs: Rosalie Sacheli, Belgium and Shivaprakas Rudramurthy, India

16:45

S6.2a The Indian epidemic: clinical and epidemiologic aspects

Shiham Verma, India

17:05

S6.2b In vitro susceptibility testing of dermatophytes: towards standardisation

Ditte Saunte, Denmark

17:25

S6.2c Dermatophyte antifungal resistance

Eric Dannaoui, France

17:45

S6.2d Dermatophytosis due to Trichophyton erinacei caused by contact with african hedgehogs as family pets

Alexandro Bonifaz, Mexico

18:00

Q&A with all speakers

S6.3 Fungal adaptation and evolution

Chair: Sijmen Schoustra, Netherlands

16:45

S6.3a Genetics and genomics of adaptive change in Aspergillus

Sijmen Schoustra, Netherlands

17:05

S6.3b Aspergillus fumigatus resistance development to triazoles in compost; an experimental evolution model

Jianhua Zhang, Netherlands

17:25

S6.3c Long-term adaptation of Aspergillus to low resource conditions resulting in non-sporulation mutant types

Krithi Nandimath, India

17:45

S6.3d Candida albicans commensalism in the oral mucosa is favoured by limited virulence and metabolic adaptation

Salomé LeibundGut-Landmann, Switzerland

18:00

Q&A with all speakers

S6.4 One health approach for endemic mycoes in the Americas

Chairs: Flavio Queiroz-Telles, Brazil and Arnaldo Lopes Colombo, Brazil

16:45

S6.4a Chromoblastomycosis as occupational disease

Daniel Wagner, Brazil

17:00

S6.4b Sporotrichosis in pediatric patients

Flavio Queiroz-Telles, Brazil

17:15

S6.4c Primary cutaneous implantation coccidioidomycosis

Alexandro Bonifaz, Mexico

17:30

S6.d Coccidioidomycosis & climate change

Tom Chiller, USA

17:45

S6.4e Discovering new histoplasmosis patients in LATAM

Diego Caceres, USA

18:00

Q&A with all speakers

S6.5 Efforts of improving the management of mycetoma: working towards the 2030 goals

Chairs: Wendy van de Sande, Netherlands and Ahmed Hassan Fahal, Sudan

16:45

S6.5a Metagenomic analysis of Sennar and White Nile states in Sudan to identify mycetoma causative agents in the surroundings

Sahar Bakhiet, Sudan

17:05

S6.5b Genomics and metagenomics of Madurella mycetomatis

Anastasia Litvintseva, USA

17:25

S6.5c MycetOS: identifying drugs which can penetrate the mycetoma grain

Wendy van de Sande, Netherlands

17:45

S6.5d Molecular identification of mycetoma causative agents from patients in hospital setting in Senegal

Doudou Sow, Senegal

18:00

Q&A with all speakers

18:15

Key note (P5): Advances in the field of aspergillosis

Paul Verweij, Netherlands

19:00

Young ISHAM dinner and party